Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Characterization and Survival of Human Infant Testicular Cells After Direct Xenotransplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Circadian Clock Is Sustained in the Thyroid Gland of VIP Receptor 2 Deficient Mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Biological and Clinical Rationale for Androgen Priming in Ovarian Stimulation

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Changes in Serum Sphingomyelin After Roux-en-Y Gastric Bypass Surgery Are Related to Diabetes Status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Effect of Bariatric Surgery on Healthcare Costs and Labor Market Attachment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide. Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models. Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA1c 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m2 were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of -2.65 kg during the trial (95% CI: -4.60; -0.69; P = 0.009). Similar significant associations were found for several HRV indices. Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.

OriginalsprogEngelsk
Artikelnummer242
TidsskriftFrontiers in Endocrinology
Vol/bind10
Antal sider9
ISSN1664-2392
DOI
StatusUdgivet - 12 apr. 2019

ID: 57074528